Patent · US Active

Antibody against claudin 18A2 and use thereof

US12415853B2 · kind B2 · utility

0Cited by

2References

18Claims

0Family size

Assignee

QILU PHARMACEUTICAL CO., LTD. · CN

Inventors

Yingying YANG · Jinan, CN
Gao-qing Li · Beijing, CN
Yaning Wang · Shandong, CN
Zhenming An · Shandong, CN
Shuyong ZHAO · Shandong, CN
Yuxue Liu · Nanjing, CN
Shicong Liu · Shandong, CN
Meijuan Zhang · Beijing, CN
Jinjin Jiang · San Jose, US

Key dates

Filing date	May 15, 2020
Grant date	Sep 16, 2025
Priority date	—
Expiry date	Nov 11, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, a derivative comprising said antibody or antigen-binding fragment thereof, a pharmaceutical composition, and related use of said antibody or antigen-binding fragment thereof for treating, diagnosing and detecting cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.